Therapeutic Potential of Engineered Virus-like Particles of Parvovirus B19.
enzyme nanocarriers
nanobiotecnology
nanomedicine
parvovirus-like particles
protein engineering
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
received:
08
07
2023
revised:
28
07
2023
accepted:
31
07
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Virus-like particles (VLPs) comprise one or many structural components of virions, except their genetic material. Thus, VLPs keep their structural properties of cellular recognition while being non-infectious. VLPs of Parvovirus B19 (B19V) can be produced by the heterologous expression of their structural proteins VP1 and VP2 in bacteria. These proteins are purified under denaturing conditions, refolded, and assembled into VLPs. Moreover, chimeric forms of VP2 have been constructed to harbor peptides or functional proteins on the surface of the particles without dropping their competence to form VLPs, serving as presenting nanoparticles. The in-vitro assembly approach offers exciting possibilities for the composition of VLPs, as more than one chimeric form of VP2 can be included in the assembly stage, producing multifunctional VLPs. Here, the heterologous expression and in-vitro assembly of B19V structural proteins and their chimeras are reviewed. Considerations for the engineering of the structural proteins of B19V are also discussed. Finally, the construction of multifunctional VLPs and their future potential as innovative medical tools are examined.
Identifiants
pubmed: 37623967
pii: pathogens12081007
doi: 10.3390/pathogens12081007
pmc: PMC10458557
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT), UNAM
ID : IN205119 and IN210022
Références
J Virol. 2023 Feb 28;97(2):e0163122
pubmed: 36749078
Vaccine. 2013 Aug 20;31(37):3872-8
pubmed: 23827313
Mol Pharm. 2020 Dec 7;17(12):4629-4636
pubmed: 33186039
Rev Med Virol. 2003 May-Jun;13(3):137-43
pubmed: 12740829
Biochimie. 2012 Mar;94(3):870-8
pubmed: 22192916
J Infect Dis. 2003 Feb 15;187(4):675-8
pubmed: 12599085
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9
pubmed: 25071169
Curr Opin Biotechnol. 2019 Dec;60:99-103
pubmed: 30807882
Mol Biotechnol. 2015 Apr;57(4):309-17
pubmed: 25389040
Annu Rev Genomics Hum Genet. 2012;13:307-35
pubmed: 22970722
Virology. 1994 Feb;198(2):477-88
pubmed: 7507280
Nat Biotechnol. 2006 Jan;24(1):79-88
pubmed: 16369541
Am J Pathol. 2000 Apr;156(4):1363-80
pubmed: 10751361
Int J Mol Sci. 2022 Aug 02;23(15):
pubmed: 35955711
Mol Biotechnol. 2019 Oct;61(10):742-753
pubmed: 31317318
Sci Adv. 2023 Jan 13;9(2):eade0869
pubmed: 36630517
J Vet Med B Infect Dis Vet Public Health. 2005 Sep-Oct;52(7-8):348-52
pubmed: 16316399
Virus Res. 2016 Sep 15;224:12-8
pubmed: 27523978
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2
pubmed: 18432775
Front Microbiol. 2022 Jan 03;12:790121
pubmed: 35046918
Vaccine. 2019 Nov 20;37(49):7256-7268
pubmed: 31570181
mSystems. 2019 Sep 24;4(5):
pubmed: 31551400
J Biotechnol. 2017 Dec 10;263:55-63
pubmed: 28935566
Science. 1991 Mar 22;251(5000):1456-64
pubmed: 2006420
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
Clin Microbiol Rev. 2002 Jul;15(3):485-505
pubmed: 12097253
In Vivo. 2006 May-Jun;20(3):319-24
pubmed: 16724664
Biochemistry. 1993 Dec 14;32(49):13531-6
pubmed: 8257688
Virology. 1995 Aug 20;211(2):359-66
pubmed: 7544049
Virus Res. 1990 Mar;15(3):197-211
pubmed: 2188463
Vaccine. 2022 Oct 6;40(42):6100-6106
pubmed: 36114131
Mol Biol Res Commun. 2016 Dec;5(4):201-214
pubmed: 28261624
Virology. 2022 May;570:57-66
pubmed: 35367742
Acta Biomater. 2015 Jun;19:166-79
pubmed: 25769228
Viruses. 2016 Sep 28;8(10):
pubmed: 27690083
J Virol. 2012 Sep;86(17):9443-53
pubmed: 22740403
J Mol Graph Model. 2017 Aug;75:316-321
pubmed: 28628857
Vaccine. 2011 Oct 6;29(43):7357-63
pubmed: 21807052
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4646-50
pubmed: 1711206
J Virol. 2021 May 5;95(14):
pubmed: 33952637
Viruses. 2022 Oct 30;14(11):
pubmed: 36366508
Chem Sci. 2017 Sep 1;8(9):6577-6582
pubmed: 28989685
J Infect Dis. 2006 Sep 15;194(6):790-4
pubmed: 16941345
J Gen Virol. 2008 Dec;89(Pt 12):3034-3038
pubmed: 19008390
Indian J Med Res. 2015 Apr;141(4):389-97
pubmed: 26112839
Cell Mol Life Sci. 2020 May;77(9):1745-1770
pubmed: 31690961
Bioconjug Chem. 2007 May-Jun;18(3):836-43
pubmed: 17407258
Cell Mol Immunol. 2022 Sep;19(9):993-1011
pubmed: 35962190
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337440
J Virol. 1994 Jul;68(7):4690-4
pubmed: 8207846
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8507-11
pubmed: 8078912
Virus Res. 2015 Apr 2;201:1-7
pubmed: 25701743
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
J Infect Dis. 1993 May;167(5):1034-44
pubmed: 8486937
Front Bioeng Biotechnol. 2023 Feb 16;11:1096363
pubmed: 36873345
Biotechnol Rep (Amst). 2021 Feb 28;29:e00605
pubmed: 33732633
J Virol. 2008 Aug;82(15):7306-12
pubmed: 18508892
Drug Discov Today. 2021 Apr;26(4):902-915
pubmed: 33383213
Proc Natl Acad Sci U S A. 1989 Oct;86(19):7601-5
pubmed: 2678109
Biotechnol Bioeng. 1996 Jan 20;49(2):130-8
pubmed: 18623563
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11628-33
pubmed: 15289612
Acta Biomater. 2016 Apr 15;35:206-14
pubmed: 26911883
Bioconjug Chem. 2011 Jan 19;22(1):67-73
pubmed: 21126069
N Engl J Med. 2004 Feb 5;350(6):586-97
pubmed: 14762186
Virus Res. 2018 Aug 15;255:1-9
pubmed: 29964063
J Virol. 2006 Dec;80(24):12017-24
pubmed: 17020940
Front Microbiol. 2014 Feb 14;5:56
pubmed: 24592259
Virol J. 2015 Aug 04;12:114
pubmed: 26239432
J Virol. 2010 Nov;84(22):11737-46
pubmed: 20826697